Breast Cancer Clinical Trial
Official title:
An Open Label Pilot Study to Evaluate the Safety and Tolerability of PANVAC-V (Vaccinia) and PANVAC-F (Fowlpox) in Combination With Sargramostim in Adults With Metastatic Carcinoma
Background:
- Many cancers produce two proteins, carcinoembryonic antigen (CEA) and mucin-1 (MUC-1).
- The PANVAC-V (PANVAC vaccinia) priming vaccine and PANVAC-F (PANVAC fowlpox) boosting
vaccine contain human genes that cause production of CEA and MUC-1, which can be used as
a target for the immune system to attack the cancer. The vaccines also contain genes
that cause production of other proteins that enhance immune activity.
- Sargramostim is a protein that boosts the immune system.
Objectives:
- To evaluate the safety and effectiveness of PANVAC-V and PANVAC-F in patients with
advanced cancer.
- To document the immune response to the vaccines and any anti-tumor responses that may
occur.
Eligibility: Patients 18 years of age and older with advanced cancer whose tumors produce CEA
or MUC-1 protein
Design:
- This trial has three cohorts: the first cohort includes 10 patients with advanced
colorectal cancer and 10 to 15 patients with any advanced non-colorectal cancer that
produces either EA or mitochondrial Ca2+ uniporter 1 (MCU-1); the second cohort includes
12 patients with advanced breast cancer and the third cohort includes 14 patients with
advanced ovarian cancer.
- All patients receive PANVAC-V on study day 1, followed by PANVAC-F on days 15, 29 and 43
then every 28 days for up to 12 vaccines followed by every 3 months until disease
progression or toxicity. The vaccines are given by injection under the skin.
Sargramostim is injected at the vaccination site on the day of each vaccination and for
the next 3 days following vaccination.
- Patients whose scans show that their disease has progressed, but who are otherwise
clinically stable may revert back to monthly injections.
- Patients undergo apheresis to collect white blood cells (lymphocytes) on day 1 and day
71 of the study to measure the immune response to the treatment. Blood is collected
through a needle placed in one arm and directed through a cell separator machine where
the lymphocytes are extracted. The rest of the blood components are returned to the
patient through the same needle.
- Patients are monitored with frequent blood tests and periodic imaging tests (scans) to
monitor for safety and the response to treatment.
Background:
- Carcinoembryonic antigen (CEA) and mucin-1 (MUC-1) are overexpressed in multiple
adenocarcinomas.
- Pox viral vectors can induce a strong immune response to CEA and MUC-1.
- The use of agonist epitopes within the tumor associated antigen (TAA) can induce a
better immune response than native peptides and have been associated with clinical
responses
- Heterologous prime and boost regimens are superior in terms of generalizing immune
responses; and this may translate into improved clinical responses
- The use of granulocyte-macrophage colony-stimulating factor (GM-CSF) does not add
significant toxicity and in pre-clinical models is essential for induction for optimal
immune responses.
- It is possible by using vectors directed against TAA that there may be additive or
synergistic immune responses and this may be important in overcoming antigenic escape
variance
- Evidence of clinical benefit has been noted in some patients treated with this vaccine
Objectives:
- For colorectal cancer and non-colorectal cancer Cohort: To evaluate the safety and
tolerability of the vaccine.
- For the Ovarian Cancer and Breast Cancer Cohorts: To evaluate clinical response to the
vaccine.
Eligibility:
- In the first cohort (colorectal and non-colorectal cancer), histologically confirmed
adenocarcinoma that is CEA or MUC-1 positive described as metastatic disease (measurable
or evaluable) or metastatic disease documented by biopsy but not evaluable by imaging
(e.g. small volume peritoneal disease)
- For the ovarian and breast cancer cohorts, patients must have evaluable disease
- Normal organ function, Eastern Cooperative Oncology Group (ECOG) 0-1
Design:
- This is a non-randomized three cohort, pilot trial of pox viral vaccines that contain
the transgenes for CEA and MUC-1 (both with modified human leukocyte antigen A2 (HLA-A2)
agonist epitopes) as well as 3 human T-cell costimulatory molecules, B7-1, ICAM-1
(CD54), and LFA-3 (CD58) [PANVAC(TM)-V (vaccinia) and PANVAC(TM)-F (fowlpox)] in
patients with metastatic carcinoma that express CEA or MUC-1 antigen.
- The first cohort will enroll 10 patients with metastatic colorectal adenocarcinoma and
10-15 patients with any metastatic non-colorectal carcinoma that expresses either CEA or
MUC-1. .
- The second cohort will enroll 12 patients with metastatic breast carcinoma and 14
patients with metastatic ovarian carcinoma.
- All patients will receive the same vaccines on the same schedule. PANVAC(TM)-V
(vaccinia) subcutaneously (s.c.) scheduled on day 1, followed by PANVAC(TM)-F (fowlpox)
s.c. scheduled on days 15, 29, and 43 then every 28 days for up to 12 vaccines followed
by every 3 months until disease progression or toxicity.
- Sargramostim (100 micro g) will be given at the site of the vaccination (PANVAC-V and
PANVAC-F) on each vaccination day and for three consecutive days thereafter.
- Patients who have radiographic evidence of progressive disease, but who are otherwise
clinically stable may revert back to monthly vaccinations.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |